This section is intended for UK healthcare professionals. If you are a member of the public click here. If you have been prescribed ADCETRIS click here.
Data were collected from 21 R/R HL patients retreated with ADCETRIS*1
* Included patients who previously achieved a CR or PR with ADCETRIS
**1 patient had no post-baseline response assessment
Adapted from Bartlett et al, 2014.
*Tumour reduction measurement available for 19 patients
Adapted from Bartlett et al. 2014
Treatment-emergent adverse events occurring in ≥20% of R/R HL patients (n=21) in this study3
n (%) | |
---|---|
Any event2 | 20 (95) |
Peripheral sensory neuropathy | 12 (57) |
Nausea | 9 (43) |
Diarrhoea | 9 (43) |
Fatigue | 11 (52) |
Headache | 6 (29) |
Peripheral motor neuropathy | 6 (29) |
Arthralgia | 7 (33) |
Dyspnoea | 7 (33) |
Pyrexia | 7 (33) |
Anaemia | 6 (29) |
Back pain | 5 (24) |
Cough | 5 (24) |
Dizziness | 5 (24) |
With the exception of higher incidence of peripheral motor neuropathy (29% total versus 11%) the rates of AEs were consistent with those observed in the pivotal phase 2 trial in R/R HL1,3
Please use the following link to access the CDF criteria for reuse
Please refer to the guidance in your local NHS service for further information on funding.
Bartlett NL, et al. J Haem Onc. 2014; 7 (24): 1-8
†ADCETRIS is licenced up to a maximum of 16 cycles2
Adverse events should be reported. In the United Kingdom, reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.
Adverse events should also be reported to Takeda on 01628 537900 or e-mail DSO-UK@takeda.com.
The link you have selected is not under the review or control of Takeda UK Ltd and, as such, the company does not endorse the content, its accuracy, or any practices or standards contained within it.
Please confirm you wish to follow this link.
You are now leaving the ADCETRIS.co.uk website. The link you have selected will now take you to the Takeda UK website.
Please confirm you wish to follow this link.
You are now leaving the ADCETRIS.co.uk website. The link you have selected will now take you to the Takeda global website. Takeda UK does not manage or maintain the content of the global website.
Please confirm you wish to follow this link.
You are now leaving the ADCETRIS.co.uk website. The link you have selected will now take you to the Takeda global website. Takeda UK does not manage or maintain the content of the global website.
Please confirm you wish to follow this link.
UK/ADC/1707/0053u(1) - August 2018